Article
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Cell reports - 27 Mar 2018
Fukumoto Takeshi, Park Pyoung Hwa, Wu Shuai, Fatkhutdinov Nail, Karakashev Sergey, Nacarelli Timothy, Kossenkov Andrew V, Speicher David W, Jean Stephanie, Zhang Lin, Wang Tian-Li, Shih Ie-Ming, Conejo-Garcia Jose R, Bitler Benjamin G, Zhang Rugang
Abstract excerpt
ARID1A, a subunit of the SWI/SNF complex, is among the most frequently mutated genes across cancer types. ARID1A is mutated in more than 50% of ovarian clear cell carcinomas (OCCCs), diseases that have no effective therapy. Here, we show that ARID1A mutation confers sensitivity to pan-HDAC inhibitors such as SAHA in ovarian cancers. This correlated with enhanced growth suppression induced by the inhibition of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.